Cargando…

Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults

Detalles Bibliográficos
Autores principales:	Liu, Xiaoqiang, Li, Yuhua, Wang, Zhongfang, Cao, Shouchun, Huang, Weijin, Yuan, Lin, Huang, Yi-Jiao, Zheng, Yan, Chen, Jingjing, Ying, Bo, Xiang, Zuoyun, Shi, Jin, Zhao, Jincun, Huang, Zhen, Qin, Cheng-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197092/ https://www.ncbi.nlm.nih.gov/pubmed/35701541 http://dx.doi.org/10.1038/s41422-022-00681-3

Ejemplares similares

Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice
por: Li, Xingxing, et al.
Publicado: (2023)

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review
por: Lv, Jingjing, et al.
Publicado: (2022)

Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
por: Sun, Shiyu, et al.
Publicado: (2021)

Construction and immunogenicity of an mRNA vaccine against chikungunya virus
por: Liu, Jingjing, et al.
Publicado: (2023)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Author Correction: Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
por: Sun, Shiyu, et al.
Publicado: (2021)

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants
por: Zhao, Zhuxiang, et al.
Publicado: (2022)

Heterologous prime-boost with AdC68- and mRNA-based COVID-19 vaccines elicit potent immune responses in mice
por: Li, Wenjuan, et al.
Publicado: (2021)

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients
por: Khoo, Nicholas Kim Huat, et al.
Publicado: (2022)

Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination
por: Chen, Yuxin, et al.
Publicado: (2021)

Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial
por: Liu, Xiaoqiang, et al.
Publicado: (2023)

Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine
por: Chen, Qian, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus
por: Fournillier, Anne, et al.
Publicado: (2013)

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
por: Lyke, Kirsten E., et al.
Publicado: (2023)

Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants
por: Zhong, Jiaying, et al.
Publicado: (2022)

Tu1269: IMMUNOGENICITY AND SAFETY OF HETEROLOGOUS VERSUS HOMOLOGOUS PRIME-BOOST REGIMENS WITH ADENOVIRAL VECTORED AND MRNA SARS-COV-2 VACCINE IN LIVER TRANSPLANT RECIPIENTS
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice
por: Tian, Siyu, et al.
Publicado: (2021)

Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis
por: Cheng, Haoyue, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study
por: Huang, Szu-Ting, et al.
Publicado: (2023)

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
por: Venkatraman, Navin, et al.
Publicado: (2019)

Heterologous Prime-Boost Vaccination Enhances TsPmy’s Protective Immunity against Trichinella spiralis Infection in a Murine Model
por: Wang, Lei, et al.
Publicado: (2017)

Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism
por: Zhang, Xintong, et al.
Publicado: (2022)

Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system
por: Nie, Jianhui, et al.
Publicado: (2017)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice
por: Li, Xingxing, et al.
Publicado: (2022)

Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia
por: Santi, Theresia, et al.
Publicado: (2022)

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
por: Liu, Xinxue, et al.
Publicado: (2021)

An Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice
por: Govea-Alonso, Dania O., et al.
Publicado: (2022)

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
por: Schmidt, Tina, et al.
Publicado: (2021)

Safety and Immunogenicity of Homologous and Heterologous Adenoviral-Vectored and mRNA COVID-19 Vaccine Regimens in Radiotherapy Patients
por: Prayongrat, Anussara, et al.
Publicado: (2023)

Advanced Oxidation Nanoprocessing Boosts Immunogenicity of Whole Tumor Cells
por: Zhang, Min, et al.
Publicado: (2023)

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
por: Tan, C. Sabrina, et al.
Publicado: (2022)

Pre‐existing heterologous T‐cell immunity and neoantigen immunogenicity
por: Leng, Qibin, et al.
Publicado: (2020)

Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan
por: Kang, Chun-Min, et al.
Publicado: (2022)

Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
por: Pan, Yuting, et al.
Publicado: (2020)

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
por: Vallée, Alexandre, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mupdhe49uk87bquqb75akc9mbn